2018年至2020年南京地区48家医院注射用升白细胞药物使用分析  

Use of Leucocyte Increasing Drugs for Injection of 48 Hospitals in Nanjing from 2018 to 2020

作　　者：史华慧 罗璨[1] 顾中盛[1] SHI Huahui;LUO Can;GU Zhongsheng(The First Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu,China 210000)

机构地区：[1]南京医科大学第一附属医院,江苏南京210000

出　　处：《中国药业》2022年第11期125-128,共4页China Pharmaceuticals

基　　金：南京药学会-常州四药医院药学科研基金[2019YX010]。

摘　　要：目的为临床合理利用注射用升白细胞药物及其医保政策的制订提供参考。方法基于江苏省医药情报研究所提供的南京地区48家医院2018年至2020年的采购数据,对注射用升白细胞药物的用药频度(DDDs)、限定日费用(DDC)、排序比等指标进行回顾性分析。结果长、短效重组人粒细胞集落刺激因子的整体DDDs较重组人粒细胞-巨噬细胞集落刺激因子高,长效聚乙二醇化重组人粒细胞集落刺激因子(3 mg)的DDDs最高,其DDC呈下降趋势,用药同步性较好。结论南京地区长、短效重组人粒细胞刺激集落因子及重组人粒细胞-巨噬细胞集落刺激因子能保障临床所需,医保调控合理、有效。Objective To provide a reference for the clinical rational use of leucocyte increasing drugs for injection and formulating the medical insurance policy for these drugs.Methods Based on the procurement data of 48 hospitals in Nanjing from 2018 to 2020 provided by Jiangsu Institute of Medical Information,the defined daily doses(DDDs),defined daity cost(DDC),B/A ratio and other indicators of leucocyte increasing drugs for injection were retrospectively analyzed.Results The overall DDDs of long-acting and short-acting recombinant human granulocyte colony-stimulating factor(rhG-CSF)were higher than those of recombinant human granulocyte-macrophage colony stimulating factor(rhGM-CSF).Long-acting PEGylated rhG-CSF(PEG-rhG-CSF)with the specification of 3 mg had the highest DDDs,a decreasing trend of DDC and good medication synchronization.Conclusion Long-acting rhG-CSF,short-acting rhG-CSF and rhGM-CSF in Nanjing can ensure clinical needs and the rational and effective regulation of medical insurance.

关 键 词：重组人粒细胞集落刺激因子 重组人粒细胞-巨噬细胞集落刺激因子 长效聚乙二醇化重组人粒细胞集落刺激因子 用药频度 限定日费用 排序比 

分 类 号：R95[医药卫生—药学] R973.4